Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial
- PMID: 25472660
- PMCID: PMC4265525
- DOI: 10.1186/1745-6215-15-474
Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial
Abstract
Background: Untreated advanced hepatocellular carcinoma (HCC) is linked to poor prognosis. While sorafenib is the current recommended treatment for advanced HCC, radioembolisation (RE; also called selective internal radiation therapy or SIRT) with yttrium-90 microspheres has shown efficacy in cohort studies. However, there are no head-to-head trials comparing radiation therapy with yttrium-90 microspheres and sorafenib in advanced HCC. The SARAH trial has been designed to compare the efficacy and safety of sorafenib therapy and RE using yttrium-90 resin microspheres (SIR-Spheres™; Sirtex Medical Limited, North Sydney, Australia) in patients with advanced HCC. Quality of life (QoL) and cost-effectiveness will also be compared between therapies.
Methods/design: SARAH is a prospective, randomised, controlled, open-label, multicentre trial comparing the efficacy of RE with sorafenib in the treatment of patients with advanced HCC. The trial aims to recruit adults with a life expectancy of >3 months, Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1, and: advanced HCC according to the Barcelona criteria (stage C) or recurrent HCC after surgical or thermoablative treatment who are not eligible for surgical resection, liver transplantation or thermal ablation; or two rounds of failed chemoembolisation. Patients will be randomised 1:1 to receive either RE or sorafenib 400 mg twice daily. All patients will be monitored for between 12 and 48 months following start of treatment. The primary endpoint of the SARAH trial is overall survival (OS). Secondary endpoints include: adverse events, progression-free survival at 6 months; tumour response rate; general or liver disease-specific QoL scores; and cost of each treatment strategy. Assuming an increase in median OS of 4 months with RE versus sorafenib therapy, randomising at least 400 patients (200 in each treatment arm) will be sufficient for 80% power and a bilateral alpha risk of 5%; therefore, 440 patients will be enrolled to allow for 10% loss of patients due to ineligibility.
Discussion: The SARAH trial is the first randomised head-to-head study to compare RE with sorafenib in advanced HCC, and will establish the potential role of RE in HCC treatment guidelines.
Trial registration: ClinicalTrials.gov identifier NCT01482442, first received 28 November 2011.
Figures
Similar articles
-
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.Lancet Oncol. 2017 Dec;18(12):1624-1636. doi: 10.1016/S1470-2045(17)30683-6. Epub 2017 Oct 26. Lancet Oncol. 2017. PMID: 29107679 Clinical Trial.
-
Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.BMC Cancer. 2016 Nov 7;16(1):856. doi: 10.1186/s12885-016-2868-y. BMC Cancer. 2016. PMID: 27821083 Free PMC article. Clinical Trial.
-
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.Cochrane Database Syst Rev. 2016 Feb 16;2:CD011313. doi: 10.1002/14651858.CD011313.pub2. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2020 Jan 24;1:CD011313. doi: 10.1002/14651858.CD011313.pub3. PMID: 26905230 Updated. Review.
-
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.Lancet Oncol. 2015 Oct;16(13):1344-54. doi: 10.1016/S1470-2045(15)00198-9. Epub 2015 Sep 8. Lancet Oncol. 2015. PMID: 26361969 Clinical Trial.
-
Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.Int J Clin Pract. 2017 Nov;71(11). doi: 10.1111/ijcp.12972. Epub 2017 Jul 30. Int J Clin Pract. 2017. PMID: 28758319 Review.
Cited by
-
Prophylactic Medication during Radioembolization in Metastatic Liver Disease: Is It Really Necessary? A Retrospective Cohort Study and Systematic Review of the Literature.Diagnostics (Basel). 2023 Dec 12;13(24):3652. doi: 10.3390/diagnostics13243652. Diagnostics (Basel). 2023. PMID: 38132236 Free PMC article.
-
Is the Y90-radioembolization treatment effective on the intermediate-advanced stage of hepatocellular carcinoma and what is the albumin-bilirubin score's prediction factor for survival?Hepatol Forum. 2023 Jun 16;4(3):103-107. doi: 10.14744/hf.2022.2022.0036. eCollection 2023. Hepatol Forum. 2023. PMID: 37822305 Free PMC article.
-
LiMAx Prior to Radioembolization for Hepatocellular Carcinoma as an Additional Tool for Patient Selection in Patients with Liver Cirrhosis.Cancers (Basel). 2022 Sep 21;14(19):4584. doi: 10.3390/cancers14194584. Cancers (Basel). 2022. PMID: 36230506 Free PMC article.
-
Selective Internal Radiation Combined with Chemotherapy Maintains the Quality of Life in Intrahepatic Cholangiocarcinomas.Curr Oncol. 2021 Nov 8;28(6):4530-4541. doi: 10.3390/curroncol28060384. Curr Oncol. 2021. PMID: 34898592 Free PMC article.
-
ALBI Score Is a Strong Predictor of Toxicity Following SIRT for Hepatocellular Carcinoma.Cancers (Basel). 2021 Jul 28;13(15):3794. doi: 10.3390/cancers13153794. Cancers (Basel). 2021. PMID: 34359695 Free PMC article.
References
-
- Cabbibo G, Enea M, Latteri F, Genco C, Craxì A, Cammá C. Survival of unresectable hepatocellular carcinoma: a meta-analysis of the control arms of 28 randomized trials. J Hepatol. 2009;50:S285. doi: 10.1016/S0168-8278(09)60780-7. - DOI
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical